Sodium-Glucose Cotransporter 2 Inhibitors
in the Treatment of Type 2 Diabetes
Volume 1 - Issue 3
Nikolaos Papanas* and Theano Penlioglou
-
Author Information
Open or Close
- Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, Greece
*Corresponding author:
Nikolaos Papanas, Diabetes Centre, Second Department of Internal Medicine, Democritus University of Thrace,
University Hospital of Alexandroupolis, G Kondyli 22c, Alexandroupolis 68100, Greece
Received: June 20, 2018; Published: June 27, 2018
DOI: 10.32474/ADO.2018.01.000111
Full Text
PDF
To view the Full Article Peer-reviewed Article PDF
Abstract
Over the past years, type 2 diabetes mellitus (T2DM) has become
a global pandemic, both in developed and developing countries
[1,2]. Its aetiology is multifactorial, including genetic factors,
increasing age, obesity and insulin resistance [3]. Among these
factors, obesity is of paramount importance, and its management
can be of benefit [4,5].
Editorial|
Conflicts of Interest|
References|